Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06031805 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PRostate Olaparib Real World Evidence Study

Study acronym: PROWESs
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Trial sites reduced: 65 → 39 locations · Final enrollment: 159 participants (planned 300) · Eligibility criteria expanded, about 8 words · 1 more Show 4 more changesShow less
    • Trial sites reduced: 65 → 39 locations
    • Final enrollment: 159 participants (planned 300)
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 6 of 28 entries
  2. Site details revised at 15 of 65 sitesv21
  3. Re-verified, no change to tracked fieldsv20
  4. Eligibility criteria expanded, about 58 words Secondary endpoints expanded, about 126 wordsv19 Show 1 more changeShow less
    • Secondary endpoints expanded, about 126 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 63 to 65v18
Show 16 earlier versionsHide 16 earlier versions
  1. Study sites: 62 to 63v17
  2. Site details revised at 15 of 62 sitesv16
  3. Site details revised at 33 of 62 sitesv15
  4. Study sites: 23 to 62v14
  5. Study sites: 62 to 23v13
  6. Study sites: 61 to 62v12
  7. Study sites: 56 to 61v11
  8. Study sites: 51 to 56v10
  9. Study sites: 50 to 51v9
  10. Study sites: 48 to 50v8
  11. Study sites: 42 to 48v7
  12. Study sites: 40 to 42v6
  13. Study sites: 38 to 40v5
  14. Study sites: 54 to 38v4
  15. Re-verified, no change to tracked fieldsv3
  16. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 54 · Start date changed from estimate of Oct 13, 2023 to Oct 11, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 54
    • Start date changed from estimate of Oct 13, 2023 to Oct 11, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
This French non-interventional longitudinal multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of treatment sequencing, effectiveness, safety and BRCA testing patterns and thus inform future clinical practice.
Trial Details
NCT Number NCT06031805
Lead Sponsor AstraZeneca
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 159 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov